Cargando…

Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women

BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Upson, Kristen, Harmon, Quaker E., Heffron, Renee, Hall, Janet E., Wise, Lauren A., Wegienka, Ganesa, Tokar, Erik J., Baird, Donna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Environmental Health Perspectives 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673223/
https://www.ncbi.nlm.nih.gov/pubmed/33206002
http://dx.doi.org/10.1289/EHP7017
_version_ 1783611281298685952
author Upson, Kristen
Harmon, Quaker E.
Heffron, Renee
Hall, Janet E.
Wise, Lauren A.
Wegienka, Ganesa
Tokar, Erik J.
Baird, Donna D.
author_facet Upson, Kristen
Harmon, Quaker E.
Heffron, Renee
Hall, Janet E.
Wise, Lauren A.
Wegienka, Ganesa
Tokar, Erik J.
Baird, Donna D.
author_sort Upson, Kristen
collection PubMed
description BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead. OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations. METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23–35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent difference in blood lead concentrations and 95% confidence intervals (CI) between current DMPA users and nonusers using multivariable linear regression. RESULTS: Geometric mean blood lead concentration was [Formula: see text] (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, and history of medical conditions or current medication use associated with bone loss. DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoffs between the adverse effects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy. https://doi.org/10.1289/EHP7017
format Online
Article
Text
id pubmed-7673223
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Environmental Health Perspectives
record_format MEDLINE/PubMed
spelling pubmed-76732232020-11-20 Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women Upson, Kristen Harmon, Quaker E. Heffron, Renee Hall, Janet E. Wise, Lauren A. Wegienka, Ganesa Tokar, Erik J. Baird, Donna D. Environ Health Perspect Research BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead. OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations. METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23–35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent difference in blood lead concentrations and 95% confidence intervals (CI) between current DMPA users and nonusers using multivariable linear regression. RESULTS: Geometric mean blood lead concentration was [Formula: see text] (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, and history of medical conditions or current medication use associated with bone loss. DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoffs between the adverse effects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy. https://doi.org/10.1289/EHP7017 Environmental Health Perspectives 2020-11-18 /pmc/articles/PMC7673223/ /pubmed/33206002 http://dx.doi.org/10.1289/EHP7017 Text en https://ehp.niehs.nih.gov/about-ehp/license EHP is an open-access journal published with support from the National Institute of Environmental Health Sciences, National Institutes of Health. All content is public domain unless otherwise noted.
spellingShingle Research
Upson, Kristen
Harmon, Quaker E.
Heffron, Renee
Hall, Janet E.
Wise, Lauren A.
Wegienka, Ganesa
Tokar, Erik J.
Baird, Donna D.
Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title_full Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title_fullStr Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title_full_unstemmed Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title_short Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women
title_sort depot medroxyprogesterone acetate use and blood lead levels in a cohort of young women
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673223/
https://www.ncbi.nlm.nih.gov/pubmed/33206002
http://dx.doi.org/10.1289/EHP7017
work_keys_str_mv AT upsonkristen depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT harmonquakere depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT heffronrenee depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT halljanete depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT wiselaurena depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT wegienkaganesa depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT tokarerikj depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen
AT bairddonnad depotmedroxyprogesteroneacetateuseandbloodleadlevelsinacohortofyoungwomen